[go: up one dir, main page]

WO1999066909A3 - Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme - Google Patents

Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Download PDF

Info

Publication number
WO1999066909A3
WO1999066909A3 PCT/CA1999/000567 CA9900567W WO9966909A3 WO 1999066909 A3 WO1999066909 A3 WO 1999066909A3 CA 9900567 W CA9900567 W CA 9900567W WO 9966909 A3 WO9966909 A3 WO 9966909A3
Authority
WO
WIPO (PCT)
Prior art keywords
apomorphine
vaginal
hydroxytryptamine
diminished
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000567
Other languages
English (en)
Other versions
WO1999066909A2 (fr
Inventor
Michael A. Adams
Jeremy P. W. Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Queens University at Kingston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University at Kingston filed Critical Queens University at Kingston
Priority to EP99957146A priority Critical patent/EP1089736A2/fr
Priority to JP2000555595A priority patent/JP2002518435A/ja
Priority to AU42547/99A priority patent/AU4254799A/en
Priority to CA002334550A priority patent/CA2334550A1/fr
Priority to MXPA01000275A priority patent/MXPA01000275A/es
Publication of WO1999066909A2 publication Critical patent/WO1999066909A2/fr
Publication of WO1999066909A3 publication Critical patent/WO1999066909A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un procédé de traitement des dysfonctionnements sexuels de la femme dont: les symptômes vasculogènes d'un engorgement vaginal retardé, une lubrification réduite du vagin, des rapports douloureux ou désagréables (dyspareunie), des sensations vaginales réduites, un orgasme vaginal atténué, des sensations clitoridiennes réduites, un orgasme clitoridien atténué, et de combat des douleurs vaginales, en stimulant la libération d'oxyde d'azote par le nerf pelvien périphérique. Le procédé consiste à administrer à la femme le nécessitant une dose à effet thérapeutique d'un composé agissant sur une voie mésencéphalique pour accroître le flux sanguin dans le lit vasculaire des artères iliaques, hypogastriques, et honteuses et stimuler la libération de NO par les cellules des nerfs NANC périphériques. Le composé préféré à cette fin est l'apomorphine ou l'un de ses sels, esters ou précurseurs pharmacocompatibles. Il est également possible d'associer l'apomorphine à une quantité potentialisante d'androgène, de préférence de testostérone, prise soit avant, soit avec l'apomorphine.
PCT/CA1999/000567 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Ceased WO1999066909A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99957146A EP1089736A2 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
JP2000555595A JP2002518435A (ja) 1998-06-22 1999-06-21 女性の性機能不全の治療または改善のための方法および組成物
AU42547/99A AU4254799A (en) 1998-06-22 1999-06-21 Method and compositions for the treatment or amelioration of female sexual dysfunction
CA002334550A CA2334550A1 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
MXPA01000275A MXPA01000275A (es) 1998-06-22 1999-06-21 Metodo y composiciones para el tratamiento o alivio de disfunciones sexuales femeninas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10298798A 1998-06-22 1998-06-22
US09/102,987 1998-06-22

Publications (2)

Publication Number Publication Date
WO1999066909A2 WO1999066909A2 (fr) 1999-12-29
WO1999066909A3 true WO1999066909A3 (fr) 2000-06-29

Family

ID=22292763

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000567 Ceased WO1999066909A2 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme

Country Status (7)

Country Link
EP (1) EP1089736A2 (fr)
JP (1) JP2002518435A (fr)
AR (1) AR019694A1 (fr)
AU (1) AU4254799A (fr)
CA (1) CA2334550A1 (fr)
MX (1) MXPA01000275A (fr)
WO (1) WO1999066909A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
BR0109515A (pt) * 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
FI20002756A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Uusi hoitomenetelmä
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
GB0204919D0 (en) * 2002-03-01 2002-04-17 Cst Medical Ltd Treatment of female sexual dysfunction
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0172697A2 (fr) * 1984-08-02 1986-02-26 Eli Lilly And Company Octahydro-oxazolo[4,5-g]quinoléines
WO1987004621A1 (fr) * 1986-02-04 1987-08-13 Ekkehard Othmer Traitement du dysfonctionnement sexuel avec de la buspirone
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0172697A2 (fr) * 1984-08-02 1986-02-26 Eli Lilly And Company Octahydro-oxazolo[4,5-g]quinoléines
WO1987004621A1 (fr) * 1986-02-04 1987-08-13 Ekkehard Othmer Traitement du dysfonctionnement sexuel avec de la buspirone
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FERRARI, F. ET AL: "Influence of apomorphine on rat female sexual behavior and its relation with induction of stereotypy", RIV. FARMACOL. TER. (1977), 8(4), 355-63, XP002121202 *
GOLDSTEIN I. ET AL: "Vasculogenic female sexual dysfunction: Vaginal engorgement and clitoral erectile insufficiency syndromes.", INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, (1998) 10/SUPPL. 2 (S84-S90)., XP002121200 *
HAMBURGER-BAR, R.; RIGTER, H.: "Apomorphine: Facilitation of sexual behaviour in female rats", EUROPEAN JOURNAL OF PHARMACOLOGY, XP002121204 *
MELIS M.R. ET AL: "Dopamine and sexual behavior.", NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, (1995) 19/1 (19-38)., XP002121203 *
SEGRAVES R.T. ET AL: "Pharmacotherapy for sexual disorders: Advantages and pitfalls.", SEXUAL AND MARITAL THERAPY, (1998) 13/3 (295-309)., XP002121201 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125816B2 (en) 2000-08-30 2015-09-08 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism
US9132089B2 (en) 2000-08-30 2015-09-15 Besins Healthcare Inc. Pharmaceutical composition and method for treating hypogonadism

Also Published As

Publication number Publication date
WO1999066909A2 (fr) 1999-12-29
EP1089736A2 (fr) 2001-04-11
AR019694A1 (es) 2002-03-13
JP2002518435A (ja) 2002-06-25
MXPA01000275A (es) 2002-04-24
CA2334550A1 (fr) 1999-12-29
AU4254799A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
WO1999066909A3 (fr) Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme
PE20010924A1 (es) Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina
NZ522368A (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
MXPA00007447A (es) Tratamiento de disfuncion sexual femenina.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2002051420A3 (fr) Techniques et formulations pour le traitement de dysfonctionnements sexuels chez la femme
MY136841A (en) Carbamate-substituted pyrazolopyridines
CA2383785A1 (fr) Techniques d'utilisation d'inhibiteurs selectifs de recaptage de serotonine a apparition rapide pour traiter un dysfonctionnement sexuel
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
WO2005013914A3 (fr) Compositions utilisees comme inhibiteurs de canaux sodium voltage dependants
MXPA05003104A (es) Hidromorfonas n-sustituidas y uso de las mismas.
BG105664A (en) Use of apomophines for the treatment of organic erectile dysfunction in males
WO2001000221A3 (fr) Methodes therapeutiques et compositions pour le traitement de troubles interpersonnels et du comportement
IN2005KO00312A (fr)
EP1108426A3 (fr) Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
AU764009B2 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO2002041894A3 (fr) Utilisation d'agonistes selectifs des recepteur d4 de la dopamine dans le traitement de dysfonctions sexuelles
PL372096A1 (en) Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
SE0200475D0 (sv) Oral farmaceutisk beredning
MY134074A (en) Pharmaceutical composition comprising gamma-butyrobetaine for treatment of impotence
AU2024223859A1 (en) Compositions and methods of treating female sexual dysfunction and female sexual arousal disorder
TW200621231A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
AU2003204720B2 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
MY155220A (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
BG106619A (en) Composition of a sedative of an analgetic, suitable in particular in headache and migraine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2334550

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000275

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 42547/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999957146

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999957146

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999957146

Country of ref document: EP